Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

Bithionol inhibits ovarian cancer cell growth In Vitro- studies on mechanism(s) of action

Authors: Vijayalakshmi N Ayyagari, Laurent Brard

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

Drug resistance is a cause of ovarian cancer recurrence and low overall survival rates. There is a need for more effective treatment approaches because the development of new drug is expensive and time consuming. Alternatively, the concept of ‘drug repurposing’ is promising. We focused on Bithionol (BT), a clinically approved anti-parasitic drug as an anti-ovarian cancer drug. BT has previously been shown to inhibit solid tumor growth in several preclinical cancer models. A better understanding of the anti-tumor effects and mechanism(s) of action of BT in ovarian cancer cells is essential for further exploring its therapeutic potential against ovarian cancer.

Methods

The cytotoxic effects of BT against a panel of ovarian cancer cell lines were determined by Presto Blue cell viability assay. Markers of apoptosis such as caspases 3/7, cPARP induction, nuclear condensation and mitochondrial transmembrane depolarization were assessed using microscopic, FACS and immunoblotting methods. Mechanism(s) of action of BT such as cell cycle arrest, reactive oxygen species (ROS) generation, autotaxin (ATX) inhibition and effects on MAPK and NF-kB signalling were determined by FACS analysis, immunoblotting and colorimetric methods.

Results

BT caused dose dependent cytotoxicity against all ovarian cancer cell lines tested with IC50 values ranging from 19 μM – 60 μM. Cisplatin-resistant variants of A2780 and IGROV-1 have shown almost similar IC50 values compared to their sensitive counterparts. Apoptotic cell death was shown by expression of caspases 3/7, cPARP, loss of mitochondrial potential, nuclear condensation, and up-regulation of p38 and reduced expression of pAkt, pNF-κB, pIκBα, XIAP, bcl-2 and bcl-xl. BT treatment resulted in cell cycle arrest at G1/M phase and increased ROS generation. Treatment with ascorbic acid resulted in partial restoration of cell viability. In addition, dose and time dependent inhibition of ATX was observed.

Conclusions

BT exhibits cytotoxic effects on various ovarian cancer cell lines regardless of their sensitivities to cisplatin. Cell death appears to be via caspases mediated apoptosis. The mechanisms of action appear to be partly via cell cycle arrest, ROS generation and inhibition of ATX. The present study provides preclinical data suggesting a potential therapeutic role for BT against recurrent ovarian cancer.
Appendix
Available only for authorised users
Literature
1.
American Cancer Society: Cancer facts and figures 2013. Atlanta, Ga. American Cancer Society. 2013, 18-
2.
Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin. 2010, 60 (5): 277-300. 10.3322/caac.20073.CrossRefPubMed
3.
Herzog TJ: The current treatment of recurrent ovarian cancer. Curr Oncol Rep. 2006, 8 (6): 448-454. 10.1007/s11912-006-0074-9.CrossRefPubMed
4.
Agarwal R, Kaye SB: Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer. 2003, 3 (7): 502-516. 10.1038/nrc1123.CrossRefPubMed
5.
McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996, 34: 1-6.CrossRef
6.
Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, et al: Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial EOC: three-year results. J Natl Cancer Inst. 2000, 92: 699-708. 10.1093/jnci/92.9.699.CrossRefPubMed
7.
Kikuchi Y: The mechanism of cisplatin-resistance in ovarian cancer. Hum Cell. 2001, 14 (2): 115-133.PubMed
8.
Leitao MM, Hummer A, Dizon DS, Aghajanian C, Hensley M, Sabbatini P, Venkatraman E, Spriggs DR: Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy. Gynecol Oncol. 2003, 91: 123-129. 10.1016/S0090-8258(03)00464-5.CrossRefPubMed
9.
Lamberth E, Gregory WM, Nelstrop AE, Rustin GJ: Long-term survival in 463 women treated with platinum analogs for advanced epithelial carcinoma of the ovary: life expectancy compared to women of an age-matched normal population. Int J Gynecol Cancer. 2004, 14: 772-778. 10.1111/j.1048-891X.2004.014507.x.CrossRef
10.
Ott I, Gust R: Non platinum metal complexes as anti-cancer drugs. Arch Pharm. 2007, 340: 117-126. 10.1002/ardp.200600151.CrossRef
11.
Bacq Y, Besnier JM, Duong TH, Pavie G, Metman EH, Choutet P: Successful treatment of acute fascioliasis with bithionol. Hepatology. 1991, 14: 1066-1069. 10.1002/hep.1840140620.CrossRefPubMed
12.
Braddock D: Autotaxin and lipid signaling pathways as anticancer targets. Curr Opin Investig Drugs. 2010, 11: 629-637.PubMed
13.
Saunders LP, Ouellette A, Bandle R, Chang WC, Zhou H, Misra RN, De La Cruz EM, Braddock DT: Identification of small-molecule inhibitors of autotaxin that inhibit melanoma cell migration and invasion. Mol Cancer Ther. 2008, 7 (10): 3352-3362. 10.1158/1535-7163.MCT-08-0463.CrossRefPubMed
14.
Miller SC, Huang R, Sakamuru S, Shukla SJ, Attene-Ramos MS, Shinn P, Van Leer D, Leister W, Austin CP, Xia M: Identification of known drugs that act as inhibitors of NF-kappaB signaling and their mechanism of action. Biochem Pharmacol. 2010, 79 (9): 1272-1280. 10.1016/j.bcp.2009.12.021.CrossRefPubMedPubMedCentral
15.
Kasibhatla S, Amarante-Mendes GP, et al: Staining of suspension cells with Hoechst 33258 to detect apoptosis. CSH Protoc. 2006, 2006 (3): doi:10.1101/pdb.prot4492
16.
Razzell WE, Khorana HG: Studies on polynucleotides. III. Enzymatic degradation; substrate specificity and properties of snake venom phosphodiesterase. J Biol Chem. 1959, 234: 2105-2113.PubMed
17.
Lowry OH, Rosebrough NJ, Farr A, Randall RJ: Protein measurement with the folin phenol reagent. J Biol Chem. 1951, 193 (1): 265-275.PubMed
18.
Yokogawa M, Yoshimura H, Okura T, Sano M, Tsuji M, Iwasaki M, Hirose H: Chemotherapy of paragonimiasis with bithionol. II. Clinical observations on the treatment with bithionol. Jap J Parasitol. 1961, 10: 317-
19.
Arts HJ, Van Der Zee AG, De Jong S, De Vries EG: Options for modulation of drug resistance in ovarian cancer. Int J Gynecol Cancer. 2000, 10 (S1): 47-52. 10.1046/j.1525-1438.2000.99511.x.CrossRefPubMed
20.
Deigner HP, Kinscherf R: Modulating apoptosis: current applications and prospects for future drug development. Curr Med Chem. 1999, 6: 399-414.PubMed
21.
Kaufmann SH, Earnshaw WC: Induction of apoptosis by cancer chemotherapy. Exp Cell Res. 2000, 256: 42-49. 10.1006/excr.2000.4838.CrossRefPubMed
22.
Kaufmann SH, Gores GJ: Apoptosis in cancer: cause and cure. Bioessays. 2000, 22: 1007-1017. 10.1002/1521-1878(200011)22:11<1007::AID-BIES7>3.0.CO;2-4.CrossRefPubMed
23.
Zamzami N, Marchetti P, Castedo M, Decaudin D, Macho A, Hirsch T, Susin SA, Petit PX, Mignotte B, Kroemer G: Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death. J Exp Med. 1995, 182 (2): 367-377. 10.1084/jem.182.2.367.CrossRefPubMed
24.
Englert RP, Shacter E: Distinct modes of cell death induced by different reactive oxygen species: amino acyl chloramines mediate hypochlorous acid-induced apoptosis. J Biol Chem. 2002, 277: 20518-20526. 10.1074/jbc.M200212200.CrossRefPubMed
25.
Buolamwini JK: Cell cycle molecular targets in novel anticancer drug discovery. Curr Pharm Des. 2000, 6: 379-392. 10.2174/1381612003400948.CrossRefPubMed
26.
McDonald ER, El-Deiry WS: Cell cycle control as a basis for cancer drug development. Int J Oncol. 2000, 16: 871-886.PubMed
27.
Sherr CJ, Roberts JM: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999, 13: 1501-1512. 10.1101/gad.13.12.1501.CrossRefPubMed
28.
Goyeneche AA, Caron RW, Telleria CM: Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo. Clin Cancer Res. 2007, 13 (11): 3370-3379. 10.1158/1078-0432.CCR-07-0164.CrossRefPubMedPubMedCentral
29.
Jacks T, Weinberg RA: Cell-cycle control and its watchman. Nature (London). 1996, 381: 643-644. 10.1038/381643a0.CrossRef
30.
Sherr CJ: G1 phase progression: cycling on cue. Cell. 1994, 79: 551-555. 10.1016/0092-8674(94)90540-1.CrossRefPubMed
31.
Sherr CJ, Roberts JM: Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 1995, 9: 1149-1163. 10.1101/gad.9.10.1149.CrossRefPubMed
32.
Harper JW, Elledge SJ, Keyomarsi K, Dynlacht B, Tsai LH, Zhang P, Dobrowolski S, Bai C, Connell CL, Swindell E, Fox MP, Wei N: Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell. 1995, 6: 387-400. 10.1091/mbc.6.4.387.CrossRefPubMedPubMedCentral
33.
Conklin KA: Chemotherapy-associated oxidative stress: Impact on chemotherapeutic effectiveness. Integr Cancer Ther. 2004, 3: 294-300. 10.1177/1534735404270335.CrossRefPubMed
34.
Meshkini A, Yazdanparast R: Involvement of oxidative stress in taxol-induced apoptosis in chronic myelogenous leukemia K562 cells. Exp Toxicol Pathol. 2012, 64 (4): 357-365. 10.1016/j.etp.2010.09.010.CrossRefPubMed
35.
Berndtsson M, Hagg M, Panaretakis T, Havelka AM, Shoshan MC, Linder S: Acute apoptosis by cisplatin requires induction of reactive oxygen species but is not associated with damage to nuclear DNA. Int J of Cancer. 2007, 120 (1): 175-180. 10.1002/ijc.22132.CrossRef
36.
Watson AS, Mortensen M, Simon AK: Autophagy in the pathogenesis of myelodysplastic syndrome and acute myeloid leukemia. Cell Cycle. 2011, 10 (11): 1719-1725. 10.4161/cc.10.11.15673.CrossRefPubMedPubMedCentral
37.
Irani K: Oxidant signaling in vascular cell growth, death, and survival: a review of the roles of reactive oxygen species in smooth muscle and endothelial cell mitogenic and apoptotic signaling. Circ Res. 2000, 87: 179-183. 10.1161/01.RES.87.3.179.CrossRefPubMed
38.
Godwin P, Baird AM, Heavey S, Barr MP, O’Byrne KJ, Gately K: Targeting nuclear factor-kappa B to overcome resistance to chemotherapy. Front Oncol. 2013, 3 (120): 1-10.
39.
Page CH, Lin J, Jin Y, Castle VP, Nunez G, Huang M, Lin J: Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis. Anticancer Res. 2000, 20: 407-416.PubMed
40.
Lee S, Choi EJ, Jin C, Kim DH: Activation of PI-3 K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol Oncol. 2005, 97: 26-34. 10.1016/j.ygyno.2004.11.051.CrossRefPubMed
41.
Rokudai S, Fujita N, Kitahara O, Nakamura Y, Tsuruo T: Involvement of FKHR-dependent TRADD expression in chemotherapeutic drug-induced apoptosis. Mol Cell Biol. 2002, 22 (24): 8695-8708. 10.1128/MCB.22.24.8695-8708.2002.CrossRefPubMedPubMedCentral
42.
Asselin E, Mills GB, Tsang BK: XIA P regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. Cancer Res. 2001, 61 (5): 1862-1868.PubMed
43.
Bharti AC, Aggarwal BB: Chemopreventive agents induce suppression of nuclear factor-kappaB leading to chemo sensitization. Ann N Y Acad Sci. 2002, 973: 392-395. 10.1111/j.1749-6632.2002.tb04671.x.CrossRefPubMed
44.
Wang CY, Cusack JC, Liu R, Baldwin AS: Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nat Med. 1999, 5: 412-417. 10.1038/7410.CrossRefPubMed
45.
Cusack JC, Liu R, Baldwin AS: NF-κB and chemoresistance: potentiation of cancer drugs via inhibition of NF-κB. Drug Resist Updat. 1999, 2: 271-273. 10.1054/drup.1999.0094.CrossRefPubMed
46.
Toledano MB, Leonard WJ: Modulation of transcription factor NF-kappa B binding activity by oxidation-reduction in vitro. Proc Natl Acad Sci USA. 1991, 88 (10): 4328-4332. 10.1073/pnas.88.10.4328.CrossRefPubMedPubMedCentral
47.
Liu J, Yoshida Y, Yamashita U: DNA-binding activity of NF-kappaB and phosphorylation of p65 are induced by N-acetylcysteine through phosphatidylinositol (PI) 3-kinase. Mol Immunol. 2008, 45 (15): 3984-3989. 10.1016/j.molimm.2008.06.012.CrossRefPubMed
48.
Vermeulen L, De Wilde G, Notebaert S, Vanden Berghe W, Haegeman G: Regulation of the transcriptional activity of the nuclear factor-kappaB p65 subunit. Biochem Pharmacol. 2002, 64 (5–6): 963-970.CrossRefPubMed
49.
Cheng JQ, Jiang X, Fraser M, Li M, Dan HC, Sun M, Tsang BK: Role of X-linked inhibitor of apoptosis protein in chemoresistance in ovarian cancer: possible involvement of the phosphoinositide-3 kinase/Akt pathway. Drug Resist Updat. 2002, 5 (3–4): 131-146.CrossRefPubMed
50.
Witham J, Valenti MR, De-Haven-Brandon AK, Vidot S, Eccles SA, Kaye SB, Richardson A: The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin. Clin Cancer Res. 2007, 13 (23): 7191-7198. 10.1158/1078-0432.CCR-07-0362.CrossRefPubMed
51.
Eliopoulos AG, Kerr DJ, Herod J, Hodgkins L, Krajewski S, Reed JC, Young LS: The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene. 1995, 11: 1217-1228.PubMed
52.
Herod JO, Eliopoulos AG, Warwick J, Niedobitek G, Young LS, Kerr DJ: The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res. 1996, 56: 2178-2184.PubMed
53.
Nam SW, Clair T, Campo CK, Lee HY, Liotta LA, Stracke ML: Autotaxin (ATX), a potent tumor mitogen, augments invasive and metastatic potential of ras-transformed cells. Oncogene. 2000, 19: 241-247. 10.1038/sj.onc.1203263.CrossRefPubMed
54.
Nam SW, Clair T, Kim YS, et al: Autotaxin (NPP-2), a metastasis-enhancing motogen, is an angiogenic factor. Cancer Res. 2001, 61: 6938-6944.PubMed
55.
Vidot S, Witham J, Agarwal R, Greenhough S, Bamrah HS, Tigyi GJ, Kaye SB, Richardson A: Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells. Cell Signal. 2010, 22 (6): 926-935. 10.1016/j.cellsig.2010.01.017.CrossRefPubMed
56.
Xu Y, Gaudette DC, Boynton JD, et al: Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin Cancer Res. 1995, 1: 1223-1232.PubMed
57.
Xu Y, Xiao YJ, Zhu K, Baudhuin LM, Lu J, Hong G, Kim KS, Cristina KL, Song L, Elson P, Markman M, Belinson J: Unfolding the pathophysiological role of bioactive lysophospholipids. Curr Drug Targets Immune Endocr Metabol Disord. 2003, 3: 23-32. 10.2174/1568008033340414.CrossRefPubMed
58.
Sengupta S, Kim KS, Berk MP, Oates R, Escobar P, Belinson J, Li W, Lindner DJ, Williams B, Xu Y: Lysophosphatidic acid downregulates tissue inhibitor of metalloproteinases, which are negatively involved in lysophosphatidic acid-induced cell invasion. Oncogene. 2007, 26: 2894-2901. 10.1038/sj.onc.1210093.CrossRefPubMed
59.
60.
Ye X, Ishii I, Kingsbury MA, Chun J: Lysophosphatidic acid as a novel cell survival/apoptotic factor. Biochim Biophys Acta. 2002, 1585: 108-113. 10.1016/S1388-1981(02)00330-X.CrossRefPubMed
61.
Tigyi G, Parrill AL: Molecular mechanisms of lysophosphatidic acid action. Prog Lipid Res. 2003, 42: 498-526. 10.1016/S0163-7827(03)00035-3.CrossRefPubMed
62.
Awada R, Rondeau P, Grès S, Saulnier-Blache JS, Lefebvre d’Hellencourt C, Bourdon E: Autotaxin protects microglial cells against oxidative stress. Free Radic Biol Med. 2012, 52 (2): 516-526. 10.1016/j.freeradbiomed.2011.11.014.CrossRefPubMed
Metadata
Title
Bithionol inhibits ovarian cancer cell growth In Vitro- studies on mechanism(s) of action
Authors
Vijayalakshmi N Ayyagari
Laurent Brard
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-61

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue

Research article

Provision of breast cancer care and survival in Germany – results from a population-based high resolution study from Saarland

Research article

Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study

Research article

MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathway

Research article

Docosahexaenoic acid-induced apoptosis is mediated by activation of mitogen-activated protein kinases in human cancer cells

Research article

Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab

Research article

IL-1β mediates MCP-1 induction by Wnt5a in gastric cancer cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits